The Asceneuron team will attend AD/PD 2023, the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders. from March 28th to April 1st, in Gothenburg, Sweden.

Our Head of Preclinical Development Bruno Permanne will present O-GLCNACASE INHIBITORS ASN90 AND ASN51 ARE MULTIMODAL DRUG CANDIDATE FOR AD AND PD at the Symposium “Exploring new targets in AD, PD and LBD” taking place on Saturday, April 1st, Hall F4-F5. The lecture is scheduled for 12:10 pm CET.